AI-generated summary
The authors report an open-label pilot trial of whole-brain transcranial photobiomodulation in 29 adults with treatment-resistant depression, delivered as 12 sessions over 4 weeks. Among 22 completers, depression scores fell on average, with 40.9% achieving clinical response and most reporting mild-to-moderate side effects, mainly headache. The study had no control group, so the authors state that larger sham-controlled trials are needed.
- Participants
- 29
- Who or what was studied
- Adult outpatients with treatment-resistant depression and moderate-to-severe depressive symptoms (MADRS score of 20 or higher)
- Wavelengths
- 810 nm
- Limits stated in the abstract
- Open-label, single-arm pilot design without a sham control group, with a small sample and per-protocol results that the authors say require confirmation in larger randomized trials.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on journals.sagepub.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 810 nm
- Power
- 12.8 W
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Transcranial photobiomodulation, Depression, Photobiomodulation, Intention-to-treat analysis, Light-emitting diode, Neuromodulation, Primary outcome, Adverse event. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.